4.3 Review

Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective

Journal

CYTOMETRY PART A
Volume 97, Issue 7, Pages 662-667

Publisher

WILEY
DOI: 10.1002/cyto.a.24047

Keywords

coronavirus; 2019-nCoV; SARS-CoV-2; COVID-19; antibody-dependent enhancement

Funding

  1. Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
  2. Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS)
  3. Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [FAPESP, 2018/08426-0]

Ask authors/readers for more resources

SARS-CoV-2 pandemic and recurrent dengue epidemics in tropical countries have turned into a global health threat. While both virus-caused infections may only reveal light symptoms, they can also cause severe diseases. Here, we review the possible antibody-dependent enhancement (ADE) occurrence, known for dengue infections, when there is a second infection with a different virus strain. Consequently, preexisting antibodies do not neutralize infection, but enhance it, possibly by triggering Fc gamma receptor-mediated virus uptake. No clinical data exist indicating such mechanism for SARS-CoV-2, but previous coronavirus infections or infection of SARS-CoV-2 convalescent with different SARS-CoV-2 strains could promote ADE, as experimentally shown for antibodies against the MERS-CoV or SARS-CoV spike S protein. (c) 2020 International Society for Advancement of Cytometry

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available